![](https://pharmashots.com/public/default-image/default-730x400.png )
Top 20 Immunology Companies of 2024
Shots:
- Immunology remains one of the most explored therapy areas. Companies focusing on immunology are steadfastly working to advance treatment options by developing drugs, vaccines, and antibodies
- In 2023, the global immunology market size was valued at $98.22B and expected to register $263.22B by 2033, with a CAGR of 10.36% from 2024 to 2033. AbbVie with $26.13B reported segment revenue ranks first in our list followed by Johnson & Johnson and Sanofi
- PharmaShots brings a concise report on the Top 20 Immunology Companies Based on 2023 Immunology Segment Total Revenue
S.No. |
Companies |
Revenue (2022) ($B) |
Revenue (2023) ($B) |
Percent Change (%) |
1 |
AbbVie |
28.92 |
26.13 |
9.63 |
2 |
Johnson & Johnson |
16.93 |
18.05 |
6.59 |
3 |
Sanofi |
10.15 |
14.22 |
40.02 |
4 |
Amgen |
10.07 |
13.31 |
32.2 |
5 |
Novartis |
12.31 |
13 |
5.65 |
6 |
Roche |
7.55 |
7.64 |
1.25 |
7 |
AstraZeneca |
5.84 |
6.39 |
9.36 |
8 |
Takeda |
4.93 |
5.58 |
13.18 |
9 |
Biogen |
6.17 |
5.40 |
12.57 |
10 |
Bristol-Myers Squibb |
3.72 |
4.20 |
12.97 |
11 |
Eli Lilly |
3.34 |
3.79 |
13.54 |
12 |
Incyte |
2.87 |
3.09 |
7.72 |
13 |
Pfizer |
3.33 |
3.02 |
9.24 |
14 |
UCB |
2.27 |
2.46 |
8.43 |
15 |
GSK |
1.38 |
1.71 |
23.85 |
16 |
Mitsubishi Tanabe Pharma |
0.84 |
1.70 |
101.77 |
17 |
Astellas |
1.49 |
1.43 |
3.9 |
18 |
Argenx |
0.40 |
1.19 |
197.16 |
19 |
Merck & Co. |
0.91 |
0.89 |
1.75 |
20 |
Organon & Co. |
0.56 |
0.65 |
16.22 |
Note: Columns 1 and 2 represent ranks and companies, while Columns 3, 4, and 5 showcase the total immunology revenue of 2022, the total revenue of 2023, and the percentage change.
20. Organon & Co.
Immunology Segment Revenue: $0.65B
Founded Year: 2020
Market Cap: $5.56B
Total Employees: 10,000
Headquarters: New Jersey, United States
Stock Exchange: NYSE
- A global healthcare company, Organon research, discovers, develops, and commercializes medicinal products for women's health
- In immunology, the company develops Arcoxia (etoricoxib) and three biosimilars Hadlima (adalimumab-bwwd), Brenzys (etanercept), & Renflexis (infliximab-abda). In 2023, the immunology revenue increased by 16.22% as compared to the 2022, mainly due to the increased sales of Renflexis and Arcoxia
- In Aug’23, Samsung Bioepis and Organon reported overall results of the interchangeability study of SB5 Humira biosimilar
19. Merck & Co.
Immunology Segment Revenue: $0.89B
Founded Year: 1891
Market Cap: $318.93B
Total Employees: 69,000
Headquarters: Rahway, New Jersey
Stock Exchange: NYSE
- Merck offers innovative therapeutic solutions by developing and producing medicines, vaccines, biological treatments, and health products for animals and humans. The corporation splits its operations into two segments: pharmaceutical and animal health
- Simponi and Remicade are the two products for autoimmune diseases under the pharmaceutical segment. In 2023, the immunology revenue of Merck decreased by 1.75% due to decreased sales of Remicade
- In 2023, Aqilion announced an exclusive license and strategic research collaboration with Merck to discover, develop, and commercialize small molecule inhibitors
18. Argenx
Immunology Segment Revenue: $1.19B
Founded Year: 2008
Market Cap: $29.81B
Total Employees: ~1400
Headquarters: Amsterdam, Netherlands
Stock Exchange: EBR
- Argenx is a commercial-stage biopharmaceutical company that focuses on developing and commercializing antibody-based therapies for the treatment of autoimmune diseases
- Argenx's immunology segment comprises VYVGART and VYVGART Hytrulo. In 2023, immunology sales increased by 197.16% as compared to 2022 owing to increased sales of VYVGART in the United States and as well in ROW
- In Nov’2023, Argenx announced the EC approval of Subcutaneous VYVGART (efgartigimod alfa and hyaluronidase-qvfc) for generalized myasthenia gravis
17. Astellas
Immunology Segment Revenue: $1.43B
Founded Year: 1923
Market Cap: $19.72B
Total Employees: ~14,500
Headquarters: Tokyo, Japan
Stock Exchange: TYO
- Astellas is a multinational pharmaceutical company that focuses on genetic regulation, immuno-oncology, blindness & regeneration, and targeted protein degradation
- Astellas’ only immunology product Prograf (tacrolimus) comes in different formulations, including Advagraf, Graceptor, and ASTAGRAF XL. In 2023, segment revenue dipped by 3.90% as compared to 2022 sales, owing to the lower sales of Prograf[AS2] mainly in Japan and the US
- In Apr’2023, Twist Bioscience extended its collaboration with Astellas by entering into a third collaboration to support antibody discovery for Immunotherapies
16. Mitsubishi Tanabe Pharma (Mitsubishi Chemical Group)
Immunology Segment Revenue: $1.70B
Founded Year: 1993
Market Cap: $8.45B
Total Employees: ~68,600
Headquarters: Osaka, Japan
Stock Exchange: TYO
- Mitsubishi Tanabe Pharma Corporation (MTPC) is the pharmaceutical division of Mitsubishi Chemical Group (MCG) that manufactures and commercializes ethical drugs
- The total immunology revenue generated by autoimmune products Stelara, Simponi & Gilenya (Royalty revenue) increased the sales by 101.77% in 2023 as compared to 2022, owing to the royalty revenue of Gilenya
- In Nov’23, Mitsubishi Tanabe Pharma Corporation entered into a license agreement with Kynexis for neuropsychiatric drug candidate MT-5356
15. GSK
Immunology Segment Revenue: $1.71B
Founded Year: 2000
Market Cap: $80.78B
Total Employees: ~70,200
Headquarters: London, United Kingdom
Stock Exchange: LON
- GSK is a British multinational biopharma company that researches, discovers, manufactures, and commercializes therapies for infectious diseases, HIV, immunology, respiratory, and cancer
- GSK's only immunology asset is Benlysta, which contributed to the total immunology sales of the company and showed an increment of 23.85% in 2023 as compared to 2022, due to strong demand for Benlysta in the US and Europe
- In Feb’23, GSK’s Benlysta received an Orphan Drug Designation from the US FDA for the possible treatment of systemic sclerosis
14. UCB
Immunology Segment Revenue: $2.46B
Founded Year: 1928
Market Cap: $31.12B
Total Employees: ~9,100
Headquarters: Brussels, Belgium
Stock Exchange: EBR
- A multinational biopharma company, UCB develops, manufactures, and commercializes therapies in neurology, immunology, and rare diseases
- In immunology, UCB has two products Cimzia & Bimzelx. UCB reported an increase of 8.43% in the segment revenue in 2023 as compared to 2022, owing to increased sales of Bimzelx
- In Oct’23, Bimzelx received the US FDA's approval for the medical care of adults with mild to severe plaque psoriasis
13. Pfizer
Immunology Segment Revenue: $3.02B
Founded Year: 1849
Market Cap: $169.88B
Total Employees: 88,000
Headquarters: New York, United States
Stock Exchange: NYSE
- Pfizer is an American multinational company that develops, manufactures, and markets medicines and vaccines. The company operates in three main segments: Primary care, specialties, and oncology
- Xeljanz, Enbrel, and Inflectra/Remsima are the products that fall in the immunology segment. In 2023 Pfizer’s immunology revenue decreased by 9.24% as compared to 2022, owing to the reduced sales of Xeljanz and Enbrel
- In Oct’2023, the US FDA approved Pfizer’s VELSIPITY for the treatment of moderately to severely active ulcerative colitis in adult patients
12. Incyte
Immunology Segment Revenue: $3.09B
Founded Year: 2002
Market Cap: $15.02B
Total Employees: ~2300
Headquarters: Delaware, United States
Stock Exchange: NASDAQ
- A global biopharmaceutical company, Incyte discovers, develops, and commercializes proprietary therapeutics. The company works in areas of Hematology/Oncology and Inflammation & Autoimmunity
- Incyte’s Jakafi, Olumiant, and Jakavi (royalty revenue) are the products approved for autoimmune indications. In 2023, the company reported an increase of 7.72% in its segment revenue as compared to 2022, owing to the increased sales of Jakafi
- In 2023, Incyte reported encouraging 52-week outcomes from a P-IIb trial assessing Povorcitinib (INCB54707) in individuals having extensive nonsegmental vitiligo
11. Eli Lilly & Company
Immunology Segment Revenue: $3.79B
Founded Year: 1876
Market Cap: $817.23B
Total Employees: 43,000
Headquarters: Indianapolis, United States
Stock Exchange: NYSE
- Eli Lilly is an American pharmaceutical company that specializes in bone and joint disease, cancer, cardiovascular disease, diabetes, endocrine illness, immunology, neurodegeneration, neurology, and pain management
- The immunology segment of Eli Lilly includes drugs like Taltz and Olumiant among others. In 2023, the immunology segment showed an incline of 13.54% in revenue as compared to 2022, due to increased sales of the above-mentioned drugs
- In 2023, Eli Lilly completed the acquisition of DICE therapeutics and expanded its immunology portfolio by including oral IL-17 inhibitors
10. Bristol-Myers Squibb
Immunology Segment Revenue: $4.20B
Founded Year: 1887
Market Cap: $90.53B
Total Employees: 34,100
Headquarters: New Jersey, United States
Stock Exchange: NYSE
- BMS is an American biopharma company that discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products on a global basis
- The company has three autoimmune products Orencia, Sotyktu, and Zeposia. Orencia contributed the most to the total immunology revenue. The company's immunology revenue in 2023 increased by 12.97% as compared to 2022, owing to the overall increased sales of autoimmune products
- In 2023, BMS and Zenas BioPharma entered into a strategic license and collaboration agreement to develop and commercialize novel bi-functional antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
09. Biogen
Immunology Segment Revenue: $5.40M
Founded Year: 1978
Market Cap: $32.91B
Total Employees: ~8700
Headquarters: Massachusetts, United States
Stock Exchange: NASDAQ
- Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative treatments for Alzheimer’s, lupus, multiple sclerosis, and other therapy areas
- Tysabri, Flixabi, Tecfidera, Vumerity, Avonex, Plegridy, Fampyra, Benepali, and Imraldi are the approved products of Biogen for autoimmune indications. In 2023, the immunology segment faced a decline of 12.57% as compared to 2022, due to low reported sales of Tecfidera
- In 2023, the FDA approved Biogen's Tofidence (tocilizumab-bavi), a biosimilar to Actemra
08. Takeda
Immunology Segment Revenue: $5.58B
Founded Year: 1781
Market Cap: $44.19B
Total Employees: ~49,300
Headquarters: Tokyo, Japan
Stock Exchange: TYO
- Takeda is a multinational pharmaceutical company that focuses on five key business areas, including Gastrointestinal, Rare diseases, PDT Immunology, Oncology, and Neuroscience
- The company's PDT Immunology segment includes immunoglobulin products and Albumin products. In 2023, the segment revenue increased by 13.18% as compared to 2022, owing to the increased sales of the PDT Immunology products
- In 2023, Takeda received US FDA approval to expand the use of Hyqvia to treat primary immunodeficiency in children
07. AstraZeneca
Immunology Segment Revenue: $6.39B
Founded Year: 1999
Market Cap: $236.64B
Total Employees: 89,900
Headquarters: Cambridge, United Kingdom
Stock Exchange: LON
- AstraZeneca discovers, develops, and commercializes medicines in oncology, cardiovascular, renal, metabolic, respiratory, and immunology, vaccines and immune therapies, and rare diseases
- Saphnelo, Soliris, and Ultomiris are AstraZeneca's immunology products. In 2023, Soliris' revenue contributed the most to the immunology segment by adding $3,145M to the revenue. In 2023, the company's immunology revenue increased by 9.36% as compared to 2022, majorly driven by the increased sales of Ultomiris
- In 2023, AstraZeneca announced its intentions to acquire Gracell Biotechnologies, which was finalized in 2024. This acquisition broadened the company's focus on cancer and autoimmune diseases
06. Roche
Immunology Segment Revenue: $7.64B
Founded Year: 1896
Market Cap: $260.23B
Total Employees: 100,000
Headquarters: Basel, Switzerland
Stock Exchange: SWX
- Roche is a global multinational healthcare company that discovers, develops, and commercializes therapeutic and diagnostic products. The company operates under two business segments, i.e. Pharmaceuticals and Diagnostics
- Actemra/RoActemra, Xolair, and MabThera/Rituxan are the products under the immunology segment of Roche. In 2023, immunology showed a slight growth in its revenue by generating 1.25% more revenue than in 2022, due to higher sales of Actemra/RoActemra and Xolair
- In 2023, Roche completed the acquisition of Telavant from Roivant, including rights to a novel TL1A-directed antibody (RVT-3101) for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease
05. Novartis
Immunology Segment Revenue: $13B
Founded Year: 1996
Market Cap: $239.30B
Total Employees: ~19,600
Headquarters: Basel, Switzerland
Stock Exchange: SWX
- An innovative medicines company, Novartis discovers, develops, and sells products in cardiovascular, renal, metabolic (CRM), immunology, neuroscience, and oncology
- Cosentyx, Xolair, Ilaris, Gilenya, Kesimpta, Mayzent, and Jakavi are the company's immunology products. In 2023, the total immunology revenue increased by 5.65% as compared to 2022, owing to the higher sales of immunology medicines
- In 2023, the US FDA approved Novartis’ Cosentyx as the first new biologic for the treatment of hidradenitis suppurativa patients
04. Amgen
Immunology Segment Revenue: $13.31B
Founded Year: 1980
Market Cap: $180.03B
Total Employees: 26,700
Headquarters: California, United States
Stock Exchange: NASDAQ
- Amgen is a global biotech company that discovers, develops, manufactures, and delivers innovative therapies. The company focuses on cardiovascular diseases, oncology, bone health, neuroscience, nephrology, and inflammation
- Enbrel, Otezla, Tavneos, Tepezza, Uplizna, Prolia, Xgeva, and Amjevita are the company’s key autoimmune products. In 2023, the immunology revenue inclined 32.2% as compared to 2022, predominantly due to the overall increased sales of all the autoimmune products
- In 2023, Amgen launched Amjevita the first biosimilar of Humira in the United States
03. Sanofi
Immunology Segment Revenue: $14.22B
Founded Year: 1956
Market Cap: $130.14B
Total Employees: ~86,100
Headquarters: Paris, France
Stock Exchange: NASDAQ
- Sanofi is a global French pharmaceutical and healthcare company that researches, develops, manufactures, and markets pharmaceutical products in immunology and inflammation, neurology, oncology, rare blood disorders, rare diseases, and vaccines
- Dupixent, Kevzara, Enjaymo, Aubagio, Thymoglobulin, and Rezurock are Sanofi's immunology products. In 2023, the segment revenue grew by 40 percent as compared to 2022 owing to increased sales of Dupixent
- In 2023, Sanofi’s anti-CD40L antibody frexalimab demonstrated positive P-II results in relapsing multiple sclerosis by reducing disease activity
02. Johnson & Johnson
Immunology Segment Revenue: $18.05B
Founded Year: 1886
Market Cap: $376.12B
Total Employees: 131,900
Headquarters: New Jersey, United States
Stock Exchange: NYSE
- Johnson & Johnson is a global healthcare company that provides new medications and MedTech solutions in oncology, immunology, neuroscience, cardiology, pulmonary hypertension, and ophthalmology
- Remicade, Simponi/Simponi Aria, Stelara, and Tremfya among others are the company's immunology products. In 2023, the immunology segment revenue increased by 6.59% as compared to 2022, owing to the higher sales of Stelara and Tremfya
- In 2023, Janssen announced encouraging topline results for JNJ-2113, an oral IL-23 receptor antagonist peptide under development for the treatment of moderate-to-severe plaque psoriasis
01. AbbVie
Immunology Segment Revenue: $26.13B
Founded Year: 2013
Market Cap: $311.16B
Total Employees: 50,000
Headquarters: Illinois, United States
Stock Exchange: NYSE
- AbbVie discovers, manufactures, and commercializes products in oncology, immunology, neuroscience, eye care, aesthetics, and other chronic and complex diseases
- Humira, Skyrizi, and Rinvoq are the three products in Abbvie’s immunology segment. In 2023, Abbvie faced a decline in its total immunology revenue by 9.63% as compared to 2022, owing to the lower sales of Humira
- In 2023, AbbVie and Anima Biotech announced a collaboration to discover and develop mRNA biology modulators against oncology and immunology targets
Sources:
- Annual reports
- SEC Filings
- Press releases
- Company websites
Market Cap Source: Google Finance (25 Jul 2024)
Currency Conversion: X-Rates
Note: Percentage Change in Segment Revenue is calculated on precise value in Millions
Related Post: https://www.pharmashots.com/15863/top-20-immunology-companies-based-on-2022-immunology-segment-total-revenue